<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343771</url>
  </required_header>
  <id_info>
    <org_study_id>11-01-0634</org_study_id>
    <nct_id>NCT01343771</nct_id>
  </id_info>
  <brief_title>Hormonal Therapy for Teens With Anorexia Nervosa</brief_title>
  <official_title>Effect of Adrenal and Gonadal Hormones on Bone Marrow and Appendicular BMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The following randomized controlled trial will examine the effects of one year of
      dehydroepiandrosterone and estrogen replacement therapy (DHEA +ERT) on bone mineral density
      (BMD) and bone marrow composition in adolescents with anorexia nervosa (AN). The
      investigators will use imaging techniques including dual-energy x-ray absorptiometry (DXA),
      peripheral quantitative computed tomography (pQCT), visual assessments of magnetic resonance
      imaging (MRI) data, MR relaxometry and magnetic resonance spectroscopy (MRS) to measure bone
      mineral density and evaluate bone marrow composition. The investigators will also collect
      serum to measure hormonal mediators of the changes observed in both bone density and bone
      marrow composition, including adrenal and gonadal steroids, insulin-like growth factors,
      growth hormone, and ghrelin, adiponectin, and leptin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blinded randomized controlled trial will include 2 treatment arms of 35 patients.
      Group 1 will receive micronized oral DHEA in a dose of 50 mg daily + ERT (0.3 mg Premarin, 1
      tablet daily for 3 months, follow by Alesse, 20 mg ethinyl estradiol + 0.1 mg levonorgestrel
      for 9 months); and Group 2 will receive placebo.There will be 12 months of therapy with
      follow up assessments every 3 months. DXA and pQCT measurements will be obtained at baseline,
      6 months, and 12 months; MRI and MRS will be performed at baseline and 1 year; serum samples
      will be obtained at baseline and every 3 months throughout the 12-month trial; psychological
      and nutrition surveys will be carried out at baseline, 6, and 12 months.

      The investigators anticipate that this study will enable us to evaluate the efficacy of oral
      DHEA + ERT as a treatment strategy to optimize peak bone mass and to prevent development of
      osteoporosis in patients with AN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Marrow Fat by MRI/MRS</measure>
    <time_frame>Baseline; M12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMD by DXA (spine, hip, whole body)</measure>
    <time_frame>Baseline; M6; M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone biomarkers</measure>
    <time_frame>Baseline; M3; M6; M9; M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMD by pQCT of tibia</measure>
    <time_frame>Baseline; M6; M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal panel (serum)</measure>
    <time_frame>Baseline; M3; M6; M9; M12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Anorexia Nervosa (AN)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA + ERT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA (Prasterone) + ERT (Aviane)</intervention_name>
    <description>Micronized oral DHEA in a dose of 50 mg daily + ERT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse, 20 mcg ethinyl estradiol + 0.1 mg levonorgestrel for 9 months)</description>
    <arm_group_label>DHEA + ERT</arm_group_label>
    <other_name>Dehydroepiandrosterone (DHEA)</other_name>
    <other_name>Estrogen Replacement Therapy (ERT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo tablet will be developed by the Children's Hospital Pharmacy. Both treatments (DHEA+ERT and placebo) will be administered in a gelatin capsule.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 11-18 years (potential subjects age 11-13 years must have a bone age x-ray
             (obtained within previous 6 months) that is 13 years or more advanced)

          -  diagnosis of AN based on DSM-IV criteria

          -  female gender

          -  postmenarchal

        Exclusion Criteria:

          -  concomitant chronic diseases which affect bone health (e.g., cystic fibrosis, celiac
             disease)

          -  use of medications known to affect bone metabolism during the last 3 months

          -  use of depot medroxyprogesterone acetate during the last 12 months

          -  current pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine M Gordon, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ecklund K, Vajapeyam S, Feldman HA, Buzney CD, Mulkern RV, Kleinman PK, Rosen CJ, Gordon CM. Bone marrow changes in adolescent girls with anorexia nervosa. J Bone Miner Res. 2010 Feb;25(2):298-304. doi: 10.1359/jbmr.090805.</citation>
    <PMID>19653811</PMID>
  </reference>
  <reference>
    <citation>Shaughnessy BF, Feldman HA, Cleveland R, Sonis A, Brown JN, Gordon CM. Oral health and bone density in adolescents and young women with anorexia nervosa. J Clin Pediatr Dent. 2008 Winter;33(2):87-92.</citation>
    <PMID>19358371</PMID>
  </reference>
  <reference>
    <citation>DiVasta AD, Ringelheim J, Bristol SK, Feldman HA, Gordon CM. Skeletal measurements by quantitative ultrasound in adolescents and young women with anorexia nervosa. J Pediatr. 2007 Mar;150(3):286-90, 290.e1.</citation>
    <PMID>17307548</PMID>
  </reference>
  <reference>
    <citation>DiVasta AD, Beck TJ, Petit MA, Feldman HA, LeBoff MS, Gordon CM. Bone cross-sectional geometry in adolescents and young women with anorexia nervosa: a hip structural analysis study. Osteoporos Int. 2007 Jun;18(6):797-804. Epub 2007 Jan 5.</citation>
    <PMID>17205221</PMID>
  </reference>
  <reference>
    <citation>Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab. 2002 Nov;87(11):4935-41.</citation>
    <PMID>12414853</PMID>
  </reference>
  <reference>
    <citation>Gordon CM, Goodman E, Emans SJ, Grace E, Becker KA, Rosen CJ, Gundberg CM, Leboff MS. Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr. 2002 Jul;141(1):64-70.</citation>
    <PMID>12091853</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Catherine M. Gordon</investigator_full_name>
    <investigator_title>Catherine M. Gordon, MD, MSc</investigator_title>
  </responsible_party>
  <keyword>Anorexia Nervosa (AN)</keyword>
  <keyword>bone density</keyword>
  <keyword>DHEA</keyword>
  <keyword>estrogen therapy</keyword>
  <keyword>eating disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

